The guideline for neoadjuvant therapy of pancreatic cancer in China (2020 edition).
10.3760/cma.j.cn112139-20200708-00549
- Collective Name:Study Group of Pancreatic Surgery in China Society of Surgery of Chinese Medical Association;Pancreatic Disease Committee of China Research Hospital Association
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocols;
Clinical research;
Multiple disciplinary team;
Neoadjuvant therapy;
Pancreatic neoplasms
- MeSH:
China;
Humans;
Neoadjuvant Therapy;
Pancreatic Neoplasms;
therapy
- From:
Chinese Journal of Surgery
2020;58(9):657-667
- CountryChina
- Language:Chinese
-
Abstract:
In order to improve the overall treatment level of pancreatic cancer in China, Study Group of Pancreatic Surgery in China Society of Surgery of Chinese Medical Association and Pancreatic Disease Committee of China Research Hospital Association have formulated the guideline for neoadjuvant therapy of pancreatic cancer in China (2020 edition). Based on the GRADE system, the guideline has conducted a discussion on the indication, regimen selection, therapeutic effect evaluation, pathological diagnosis and surgery strategy, etc. This guideline has quantified the evidence level of the current clinical researches and provided recommendations for the clinical practice in the neoadjuvant therapy of pancreatic cancer. The guideline has highlighted the role of multiple disciplinary team and represented the conversion of treatment concept in pancreatic cancer. Neoadjuvant therapy has prolonged the survival of the part of pancreatic cancer patients. However, more high-quality clinical researches are in urgent need to improve the level of evidence, optimize the clinical practice and improve the survival of patients.
